Acorda Therapeutics, Inc. (ACOR):
Acorda Therapeutics, Inc. (ACOR) closed its day with gain 1.47% and ended at the price of $17.25. ACOR stock is a part of Biotechnology industry and belongs to Healthcare sector. The stock traded volume of 2.84 million shares during its recent trading session while it’s an average volume stands around 0.96 million shares. The average numbers of shares are traded in a security per day, during the recent 3-month period. The stock has relative volume of 3.09. Relative volume is ratio between current volume and 3-month average value, intraday adjusted. The forward P/E ratio stands at 42.80. The price to sales ratio is 17.
Analysts’ consensus recommendation is observed at 2.70. Rating Scale; where 1.0 rating means Strong Buy, 2.0 rating signify Buy, 3.0 recommendation reveals Hold, 4.0 rating score shows Sell and 5.0 displays Strong Sell signal.
To evaluate the ACOR recent performance, look at its past history: the stock sticks almost -39.15% during last week. It showed the change of -36.23% in last one month. It remained at -21.23% over last 3 months. The stock performed -15.44% in last 12- months and its year to date performance is standing at -8.24%.
Relative Strength Index (RSI) is 23.63 and ATR value of company is 1.84. The stock volatility for month is 5.44% and for week it is 5.57%.The stock traded 26.84% to its 52 week low and was changed -47.73% from its 52 week high as of last close. Beta factor, which measures the riskiness of the security, was observed as 1.69. ACOR’s value Change from Open was at 4.23% with a Gap of -2.65%.
USA based company Acorda Therapeutics, Inc. (ACOR)’s latest closing price was -20.64% from the average-price of 200 days while it maintained a distance from the 50 Day Moving Average at -32.00% and -35.53% compared with the 20 Day Moving Average.
EPS Growth about ACOR:
EPS in next five year years is expected to touch 29.00% while EPS growth in past 5 year was -24.60% along with sales growth of 12.20% in the last five years.
EPS growth in next year is estimated to reach -76.93% while EPS growth estimate for this year is set at -401.70%.